Regulus Therapeutics And Collaborators Publish New Data On A Critical Role For MiR-21 In Brain Tumors

�Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced the publication of new research in the journal Molecular and Cellular Biology on the persona of the microRNA known as miR-21 in regulating certain cancer cells (1). Researchers at Regulus Therapeutics, Brigham and Women's Hospital, and other collaborators ascertained a new role for miR-21 in glioblastoma multiforme (GBM), the most malignant and aggressive form of glioma, a primary psyche tumor.


Research performed in collaboration with Brigham and Women's Hospital in Boston and other researchers demonstrated that miR-21 is creditworthy for the regulation of multiple genes associated with glioma tumour cell death, migration and invasiveness. In the peer-reviewed research, scientists showed that increased miR-21 levels in tumor cells correlated with the course or aggressiveness of the tumor; highest levels of miR-21 were associated with the most aggressive forms of GBM. To clarify the function that miR-21 plays in GBM, anti-miR-21 compounds were used to inhibit miR-21 function in human tumor cells. Inhibiting miR-21 function affected the expression of genes associated with neoplasm invasiveness, proliferation, migration and other processes exploited by tumor cells. As a whole, these data correlative miR-21 regulation with the aggressiveness of the neoplasm, and hint that miR-21 is byzantine in the regulation of many different cellular processes necessary for tumorogenesis.


"The over-expression of miR-21 is observed in a variety show of cancers, including glioblastoma, breast, lung, colon and others. In this study we were able to identify genes affected by levels of miR-21 over-expression. Further, our studies show that block miR-21 mapping disrupted many of the pathways critical for neoplasm invasiveness and proliferation," aforesaid Peter Linsley, Ph.D., Chief Scientific Officer of Regulus Therapeutics. "This new enquiry adds to a quickly growing organic structure of evidence suggesting that inhibiting the function of a single microRNA could have a profound effect on multiple disease-causing proteins, thereby busy with intact cellular pathways and defining a newfangled therapeutic plan of attack for handling of disease."


(1) Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008 Sep;28(17):5369-80. Epub 2008 Jun 30.

About microRNAs


microRNAs are a of late discovered class of genetically encoded little RNAs, roughly 20 nucleotides in length, and ar believed to regulate the expression of a big number of human genes. microRNA-based therapeutics represent a new advance for the treatment of a wide-cut range of human diseases. The inappropriate absence or presence of specific microRNAs in various cells has been shown to be associated with specific human diseases including cancer, viral infection, metabolic disorders and inflammatory disease. Targeting microRNAs with novel therapeutic agents could consequence in novel and broadly acting treatments for human diseases.

About Regulus


Regulus Therapeutics LLC is a biopharmaceutical company formed to discover, develop, and commercialize microRNA-based therapeutics. Regulus aspires to translate one of the most important new discoveries in biology into a novel new approach for advanced medicine and to establish the ahead microRNA company. Created as a reefer venture by Alnylam Pharmaceuticals and Isis Pharmaceuticals, Regulus benefits from oligonucleotide do drugs discovery expertise, an established technology, and a broad intellectual property estate created and amalgamate by its parent companies for the development and commercialization of microRNA-based therapeutics. Regulus' patent estate includes over 600 patents and more than 300 pending patent applications, pertaining in the first place to chemical modifications of oligonucleotides targeting microRNA for therapeutic applications. In improver, Regulus has collaborations with academic researchers to build on the company's understanding of more than 60 microRNAs. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to explore microRNA therapeutics for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus, founded in September 2007, maintains facilities in Carlsbad, California. For more information, see http://www.regulusrx.com.

About Isis Pharmaceuticals, Inc.


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialised the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners ar developing antisense drugs invented by Isis to plow a broad variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000� Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint possessor of Regulus Therapeutics LLC, a join venture focussed on the discovery, maturation and commercialization of microRNA therapeutics. As an trailblazer in RNA-based drug find and development, Isis is the possessor or exclusive licensee of over 1,500 issued patents world. Additional information about Isis is available at hTTP://www.isispharm.com.

About Alnylam Pharmaceuticals


Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The companionship is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the stream major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world's top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad line of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. In addition, the company is developing RNAi therapeutics for the discourse of a wide compass of disease areas, including liver cancers, hypercholesterolemia, and Huntington's disease. The company's leadership position in cardinal patents, engineering, and know-how relating to RNAi has enabled it to form major alliances with ahead companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, and Kyowa Hakko Kogyo. To reflect its prospect for key scientific, clinical, and line initiatives, Alnylam has established "RNAi 2010" which includes the company's plan to significantly expand the cathode-ray oscilloscope of delivery solutions for RNAi therapeutics, have quaternary or more programs in clinical development, and to form four or more than new major business collaborations, all by the oddment of 2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint speculation focused on the uncovering, development, and commercialization of microRNA therapeutics. Founded in 2002, Alnylam maintains military headquarters in Cambridge, Massachusetts. For more and intellectual property related to microRNA therapeutics beingness discovered and developed by Regulus. Any statement describing Isis', Alnylam's or Regulus' goals, expectations, financial or other projections, intentions or beliefs is a modern statement and should be considered an at-risk statement, including those statements that are described as such parties' goals. Such statements are subject to certain risks and uncertainties, especially those inherent in the process of discovering, development and commercializing drugs that are safe and in effect for employment as human therapeutics, and in the endeavor of building a business around such products. Such parties' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause their results to differ materially from those expressed or implied by such modern statements. Although these innovative statements reflect the salutary faith judgement of the management of each such party, these statements are based solely on facts and factors currently known by Isis, Alnylam or Regulus, as the case may be. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis', Alnylam's and Regulus' programs are described in additional item in Isis' annual paper on Form 10-K for the year ended December 31, 2007, and its quarterly report on Form 10-Q for the quarter ended June 30, 2008 and in Alnylam's yearly report on Form 10-K for the year over December 31, 2007, and its quarterly report on Form 10-Q for the quarter ended June 30, 2008, which are on file with the SEC. Copies of these and other documents are available from Isis or Alnylam.

Alnylam Pharmaceuticals


More information

• Back pain eased by good posture
• Fruit juice ‘could affect drugs’
• N.M. center to blend Eastern, Western medicine
• FDA to allow food producers to irradiate spinach, lettuce
• Tag for aggressive bowel cancer

Amy Winehouse to stop singing live, fears of �painful death�

In an interview with Sky News Television, the father of Amy Winehouse has aforementioned that the twenty-four

Three Finalists, Only One Will Live Their Gospel Dream

Kymm Lowery (Beach Park, IL), John McKoy (Monroe, NC) & Melinda Watts (Fair
Oaks, CA) Are the Final Three in American Idol(R) Gospel/Christian Style TV
Series Gospel Dream 2008 on Gospel Music Channel
Season Finale Airs Sunday Night, June 29 at 9:00 P.M. ET

ATLANTA, June 25 -- The dream of a musical career is
closer than ever for three aspiring Gospel/Christian music singers who have
made it to the finals of the Gospel Music Channel television network's
American Idol(R)-inspired talent search series Gospel Dream 2008.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080625/CLW083 )

After months of passionate music performances and intense competition,
the destiny of Kymm Lowery of Beach Park, Ill., John McKoy Jr. of Monroe,
N.C. and Melinda Watts of Fair Oaks, Calif. will be decided this Sunday,
June 29th when Gospel Music Channel crowns the winner of the third season
of Gospel Dream 2008 at 9:00 p.m. (ET/PT).

To make it to the finals, Lowery, McKoy and Watts were chosen from
among thousands of hopefuls from all Gospel/Christian styles, including
traditional, soul, rock, blues and country, who competed at auditions in
Chicago, Los Angeles, Phoenix, Miami and Atlanta; and then outlasted the 16
singers who were invited to Nashville to perform in four rounds of
televised competitions.

The new Gospel Dream winner will be chosen by Gospel/Christian music's
version of Simon, Paula and Randy: GRAMMY award-winning record
producer/songwriter Big Jim Wright, Dove and Stellar award-winning cross-
cultural worship music artist/songwriter Martha Munizzi and one of Gospel
music's most prolific talents and part of one of music's hottest production
companies (PJAM) J Moss, who have been offering their honest criticism and
praise in narrowing the competition to the final three. Fans and viewers
can vote for their favorites online to see if their choice aligns with the
judges at http://www.gospelmusicchannel.com/shows/gospeldream

Lowery, who sang Donald Lawrence's classic "Say a Prayer" to make the
finals, auditioned in Chicago, just outside her hometown of Beach Park,
Ill. J Moss calls her an "amazing talent with star potential." This is
25-year-old Lowery's second shot at her Gospel Dream. She made the top 10
during the first season of the GMC series and recorded Munizzi's "Glorious"
for the Gospel Dream 2006 season soundtrack.

"My Gospel Dream 2008 experience has been a phenomenal experience --
life- changing and at the same time -- refreshing. During the competition,
I was very focused and I believe I went to a new dimension vocally because
of the experience alone," said Lowery.

McKoy impressed judge Munizzi with his performance of Smokie Norful's
version of "Run to You," because "he comes from a place of sincerity and we
can feel your heart," she told the 34-year-old who auditioned in Atlanta.

"I've always had dreams of singing to millions of people across the
world and have never participated in anything as big as Gospel Dream
before," McKoy says. "Gospel Dream has resurrected dreams that were deep
inside me from childhood and has made me realize that those dreams were not
dead and that God surely has a purpose and a plan for my life."

Producer Wright told 29-year-old Watts after her performance of
contemporary worship song "In Christ Alone" that "you look like you are
supposed to be an artist that people are running to arenas to see." The
mother of six-month old daughter Lyric, Watts traveled from their home in
the Sacramento area of Northern Calif. to begin her Gospel Dream 2008
journey at the auditions in Los Angeles.

Says Watts: "God's grace brought me here to Gospel Dream! A lot of
faith in God and remembering that it's okay to dream even when you feel you
can't."

The winner of Gospel Dream 2008 will receive a record & music video
deal and a Royal Caribbean Cruise. Gospel Dream 2008 is hosted by popular
artist/songwriter Matthew West with backstage reporting by GMC Insider's
Kelly Sutton. Celebrity musical mentors who coached the contestants
throughout the series include PAJAM, Myron Butler, Bernie Herms, Lesley
Moore and Darlene McCoy. The Gospel Dream series was created by Executive
Producer Elvin Ross who is also the series' executive producer and musical
director.

Gospel Music Channel ( http://www.gospelmusicchannel.com ) is the
nation's first and only 24/7 television network devoted to the uplifting,
inspiring and diverse music that is Gospel/Christian music. Gospel Music
Channel is the fastest-growing network in television today and can be seen
in nearly 40 million homes on various cable systems around the country and
on DIRECTV channel 338.




See Also

• Hanson
• Health Insurance Lags in Southwest: CDC
• NYC: Many 9/11 plaintiffs not seriously ill
• Why Your Brain Craves a New Sensation

Lil Wayne, T-Pain talk collaboration

Worked together on single 'Got Money'





NEW YORK -- His new Cash Money/Universal album "Tha Carter III" is only a week old, but rapper Lil Wayne is already in talks about a collaborative project with T-Pain.
The two artists have already worked together on Lil Wayne's single "Got Money," which is No. 45 this week on Billboard's Hot R&B/Hip-Hop Songs chart.
"They've been speaking on it," Cash Money head Ron "Slim" Williams said of the album, which has no release date just yet. "I wanted to get past "Tha Carter III." Now we can sit down and get to the business of different collaborations. I just want to make sure that we have a good record."
Several years ago, Lil Wayne and rapper Juelz Santana announced plans for a collaborative album, but it never materialized. However, Santana is featured on "Tha Carter III" track "You Ain't Got Nuthin on Me," alongside rapper Fabolous.

The Happening

Improving on his last two duds, The Village and the dreadful aquatic nymph tale Lady In The Water, writer/producer/director M. Night Shyamalan gets back to the kind of eerie, paranoid thriller he so successfully mined in early efforts like The Sixth Sense and Signs. The results this time are mixed in this story of a mysterious environmental �happening� on the East Coast that is causing large groups of people to commit suicide. As he does in his most effective films, Shyamalan focuses on a core group of people who must find a way to survive these strange events. Elliot (Mark Wahlberg) is a Philadelphia science teacher already dealing with marital problems with his attractive but rather unstable wife Alma (Zooey Deschanel), now thrust into full crisis mode as he, his wife, a fellow math teacher, Julian (John Leguizamo) and Julian�s daughter Jess (Ashlyn Sanchez) hit the road by train, then car to escape the unusual plague, first thought to be a terrorist attack. The group soon realizes it is more than that, perhaps a forceful message from Mother Nature cued by the growing winds and rustling of tree leaves. Joined eventually by two older boys, Jared (Robert Bailey Jr.) and Josh (Spencer Breslin), Elliot tries to be the voice of reason as each person begins to meet their own fates on a journey into a heartland of unexplainable terror.Unlike most contemporary horror films in which actors must battle butt-ugly creatures, most of the genuine frights in this flick are left to our imagination. Here Shyamalan wants us to experience what the characters are going through the abject fear on their faces. Wahlberg is particularly good at expressing a growing feeling that events are slipping out of his control. He�s amusing in a direct encounter with a house plant he fears may now have the upper hand and in the film�s best sequence where he must convince a batty, paranoid old woman (an intense Betty Buckley) to let the group stay in her remote farmhouse. Forced to utter lines like �just when you thought there couldn�t be any more evil invented,� the quirky Deschanel has her work cut out for her but is likeable enough in the end. As a math teacher Leguizamo spends much of his screen time calculating everyone�s odds for survival until his own becomes questionable. As his daughter, Sanchez is appealing and handles herself well.Shyamalan is the heir apparent to Alfred Hitchcock--in his own mind at least. Hitch�s The Birds seems to be the template, but that 1963 classic is light years ahead in every way. Unfortunately, Shyamalan is becoming something of a one-trick pony as The Happening is basically a retread of things we�ve seen him do before. There is no question he has superior skills. He clearly gets the horror genre; he just doesn�t seem to know how to make it fresh anymore and the answer isn�t by ratcheting up the body count. Reportedly, 20th Century Fox asked him deliberately to make an R rated film (his first) and its those gore-filled elements which seem superfluous here. Do we really need to see a guy commit suicide by willingly letting some zoo lions rip off his arms? It�s glaring and out of place with the subtler aspects of the director�s style. Plus, the use of overbearing and obvious music cues (score is by James Newton Howard) shamelessly telegraphs whatever scares the movie and only serves to emphasize the shortcomings of M. Night�s sketchy screenplay. Still, as a summertime time-waster, The Happening fills the bill, but as an eco-thriller with dire warnings for humankind, it drowns in its own promising potential.

See Also

• Gultskra Artikler
• Folk - Various Artists
• K3
• Report: New AC/DC Album To Be A Wal-Mart Exclusive

George Sampson's Dad Hits Back at Claims he Has Done Nothing to Support Him

Britain's Got Talent winner George Sampson's dad, Brian, yesterday hit back at claims he has done nothing to support his son, who dances on the streets to raise money for dancing lessons.

According to his mum's side of the family, George has not spoken to his dad for two years. But the talented breakdancer paid a secret visit to Brian - in the hope that he will one day get his parents back together.

Speaking from his home in Warrington, Cheshire, window fitter Brian told Britain's Sunday People newspaper, "I've been denied access tomy kids for no reason whatsoever. That's just how it has been. I don't get a look in.

"I wanted to go down to London to watch George in the final.

"When he was on TV the other night it brought a tear to my eye. I know he'd love it if I was there but Lesley didn't want me to be.

"It's terrible only being able to see your son in the papers or on TV. None of my family has been able to enjoy the children for the past five years."

When George's parents first separated all five of their children stayed with Lesley, who lives in Birchwood, Warrington.

But Brian told how daughters Chelsea, 17, and Emily, 16, fell out with their mum and moved in with him. Now George, 14, lives with Lesley along with older brother Luke, 19, and little sister Rosie, 13.

Brian added, "We split because we weren't getting on together after 15 years of marriage. There was no-one else involved on either side.

"I still contributed financially towards looking after the children.

"I had nothing, no money for myself. I was sleeping on my parent's settee, but I still paid the mortgage."

Brian says he has been comforted by visits from his eldest son Luke and a secret visit from George two months ago.

He says, "Luke has been round. He came with George once too. I don't think his mum knew about it. All of this isn't really fair on George. He's a lovely talented lad. I know he loves his mum, but he loves his dad as well.

"I know George wants to come and see me more often.

"He's there in the middle with the other children. But I'll always be there for all of them."

After winning the ITV show, George will scoop a �100,000 prize and get to perform at the Royal Variety Performance in front of the Prince of Wales.

See Also

• Richard Shulman - Samuel Welsh
• Lit Drummer Facing Brain Cancer
• Britney’s cousin to launch singing career?
• Greg Rusedski voted off Dancing on Ice

Disney - Jake Gyllenhaal Lined Up To Play Prince Of Persia

Jake Gyllenhaal has been signed to play the lead role in the Disney adaptation of hit videogame Prince of Persia.The Donnie Darko star will play sixth ...